AbbVie Inc (ABBV)vsSeaStar Medical Holding Corporation (ICU)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ICU
SeaStar Medical Holding Corporation
$3.28
-7.08%
HEALTHCARE · Cap: $11.75M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4374482% more annual revenue ($62.82B vs $1.44M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ICU
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ICU.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 68.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -162.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ICU
The strongest argument for ICU centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 68.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ICU
The primary concerns for ICU are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while ICU is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.30 — expect wider price swings.
ICU is growing revenue faster at 68.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
SeaStar Medical Holding Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company committed to improving treatment options for chronic kidney disease through its proprietary technologies aimed at enhancing renal function and minimizing the need for invasive procedures. Operating in a growing market with significant unmet medical needs, SeaStar is dedicated to clinical innovation and excellence. Supported by a strong research and development pipeline and strategic collaborations, the company is well-positioned to make impactful advancements in renal health and expedite the commercialization of its groundbreaking therapies.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?